40 reports of this reaction
1.2% of all PIOGLITAZONE HYDROCHLORIDE reports
#19 most reported adverse reaction
THROMBOSIS is the #19 most commonly reported adverse reaction for PIOGLITAZONE HYDROCHLORIDE, manufactured by Aurobindo Pharma Limited. There are 40 FDA adverse event reports linking PIOGLITAZONE HYDROCHLORIDE to THROMBOSIS. This represents approximately 1.2% of all 3,283 adverse event reports for this drug.
Patients taking PIOGLITAZONE HYDROCHLORIDE who experience thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOSIS is a less commonly reported adverse event for PIOGLITAZONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to thrombosis, the following adverse reactions have been reported for PIOGLITAZONE HYDROCHLORIDE:
The following drugs have also been linked to thrombosis in FDA adverse event reports:
THROMBOSIS has been reported as an adverse event in 40 FDA reports for PIOGLITAZONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOSIS accounts for approximately 1.2% of all adverse event reports for PIOGLITAZONE HYDROCHLORIDE, making it a notable side effect.
If you experience thrombosis while taking PIOGLITAZONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.